StockNews.com Upgrades iCAD (NASDAQ:ICAD) to Hold

iCAD (NASDAQ:ICAD) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Thursday.

iCAD Trading Down 1.0 %

Shares of ICAD opened at $1.55 on Thursday. The business’s 50 day moving average is $1.72 and its 200 day moving average is $1.54. iCAD has a 12-month low of $1.18 and a 12-month high of $2.65. The company has a market capitalization of $41.00 million, a PE ratio of -11.88 and a beta of 1.47.

Institutional Trading of iCAD

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC grew its position in shares of iCAD by 55.6% during the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after purchasing an additional 7,604 shares in the last quarter. Essex LLC purchased a new position in iCAD during the 3rd quarter valued at approximately $216,000. Perritt Capital Management Inc. increased its stake in iCAD by 7.5% in the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock worth $225,000 after acquiring an additional 9,717 shares during the last quarter. Finally, Perritt Capital Management Inc raised its holdings in shares of iCAD by 14.2% during the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock worth $208,000 after acquiring an additional 19,917 shares in the last quarter. Hedge funds and other institutional investors own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.